IMGN is having it's best day in years today, but I'm afraid it's for the wrong reason, earnings.
Positive earning surprises are nice, but the company should be viewed based on the pipeline at this point, not the earnings which may bobble up, or down, substantially in any quarter because of milestone and licensing agreements related to trials. Certainly if Kadcyla sales started to roar their would be reason to anticipate greater earnings each quarter, but while they're rising, it's frankly slower than I ever thought it would be.
On a personal note, I think you all know I'm being treated for PH+ Acute Lymphoblastic Leukemia. I'm now in full molecular remission and hopefully next month will receive a stem cell transplant which gives me the potential of living a long and somewhat normal life. I know I'll probably be on some drugs, and being monitored closely the rest of my life, but my odds improve greatly with the transplant, so that's the direction I'm taking as long as I pass all the testing they'll be doing before it.
I continue to believe IMGN pipeline is very strong, and very undervalued. ASCO should have several presentations that demonstrate why I believe that if the Abstracts that the company said would be submitted are accepted for presentation. I'm particularly interested in IMGN529, which might ultimately be proven effective with my form of leukemia, though it's not yet being tested in it. Also the SNY drug has possibilities there as well.
Gary |
